Antibody–Drug Conjugates and Radionuclide‐Conjugated Drugs in Cancer Therapy: Mechanisms, Clinical Advances, and Future Directions
MedComm · 2026-11 · 7 (11)
DOI: 10.1002/mco2.71147 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 13.11.2026. Verfasst von Chen Fu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Laboratory Center, School of Pharmacy China Medical University Shenyang China. Die Arbeit nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China-Liaoning Joint Fund, National Natural Science Foundation of China, Doctoral Start-up Foundation of Liaoning Province.
Abstract (Originalsprache)
Targeted conjugate therapeutics link tumor‐directed vectors to cytotoxic drugs or radionuclides. Antibody–drug conjugates (ADCs) usually depend on cellular uptake and intracellular processing to deliver a pharmacological payload. Radionuclide‐conjugated drugs (RDCs) deliver radiation over an emission‐dependent range and can support imaging‐based patient selection and absorbed‐dose assessment. This review compares the two modalities through four linked areas: modular design, mechanisms of action, clinical translation, and resistance and next‐generation engineering. We examine vector pharmacokinetics, linker and chelator chemistry, payload selection, and the biological effects of beta particles, alpha particles, and Auger electrons. Randomized trials establish the clinical value of selected human epidermal growth factor receptor 2 (HER2)‐, TROP2‐, and Nectin‐4‐directed ADCs and prostate‐specific membrane antigen (PSMA)‐ and somatostatin‐receptor‐directed radioligands. Evidence for newer radionuclides, alternative targets, and combinations varies from preclinical studies to early clinical trials. The comparison separates ADC payload diffusion from physical radiation crossfire and distinguishes parent‐radionuclide chelation from recoil‐driven daughter redistribution. It also addresses imaging–therapy discordance, normal‐organ exposure, biomarkers, manufacturing, and access. The proposed framework organizes design and evidence appraisal; it is not a validated treatment‐selection model. Its practical value lies in identifying which delivery principles can be shared and which require modality‐specific validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaceutical Sciences Laboratory Center, School of Pharmacy China Medical University Shenyang China.
- Department of Pharmacology, School of Pharmacy China Medical University Shenyang China.
- Department of Thoracic Surgery Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute Shenyang China.
ORCID-Profile: Chen Fu
Förderung
- National Natural Science Foundation of China-Liaoning Joint Fund
- National Natural Science Foundation of China
- Doctoral Start-up Foundation of Liaoning Province
- Department of Science and Technology of Liaoning Province
- Department of Education of Liaoning Province
Zitieren
APA
Fu, C., Yu, L., Han, L., Miao, Y., Chen, Q., Yu, Z., Liu, H., & Wei, M. (2026). Antibody–Drug Conjugates and Radionuclide‐Conjugated Drugs in Cancer Therapy: Mechanisms, Clinical Advances, and Future Directions. MedComm, 7(11). https://doi.org/10.1002/mco2.71147
Vancouver
Fu C, Yu L, Han L, Miao Y, Chen Q, Yu Z, et al. Antibody–Drug Conjugates and Radionuclide‐Conjugated Drugs in Cancer Therapy: Mechanisms, Clinical Advances, and Future Directions. MedComm. 2026;7(11). doi:10.1002/mco2.71147
BibTeX
@article{Fu2026,
author = {Fu, Chen and Yu, Lifeng and Han, Li and Miao, Yuxi and Chen, Qiuchen and Yu, Zhaojin and Liu, Hongxu and Wei, Minjie},
title = {Antibody–Drug Conjugates and Radionuclide‐Conjugated Drugs in Cancer Therapy: Mechanisms, Clinical Advances, and Future Directions},
journal = {MedComm},
year = {2026},
volume = {7},
number = {11},
doi = {10.1002/mco2.71147}
}
EUVIMED